Company Overview and News

 
Newcomers bring decaying Kentucky distillery back to life

4h nzherald.co.nz
MILLVILLE, Ky. (AP) — The whiskey quit flowing decades ago from a landmark Kentucky distillery housed in a picturesque castle. Nearly a half-century of neglect reduced the one-time tourist draw to a decaying relic.
BF.B BF.A BFA

 
Despite Drop, Brown-Forman Still Looks Expensive

2018-09-16 seekingalpha
Brown-Forman (BF.B) is a company we’ve always admired both from an investment perspective and as a consumer. We’ve owned the stock off and on over the years, but recently sold out. I know it seems like just yesterday (actually August of 2017) that we wrote an article saying the stock could be a good buy at that point. We sold out gradually from January 2018 through April of 2018 as the stock appreciated almost 40%.
BF.B

1
Monday’s Biggest Winners and Losers in the S&P 500

2018-09-10 247wallst
September 10, 2018: The S&P 500 closed up 0.2% at 2,877.28. The DJIA closed down 0.2% at 25,857.07. Separately, the Nasdaq was up 0.3% at 7,924.15.
BF.B BF.A BFA URI

 
Dwindling business confidence a global issue

2018-09-04 nzherald.co.nz
Factories from Asia to Europe are staring into the unknown when it comes to trade, and it's unnerving them.
BF.B BF.A BFA

1
6 Most Important Things In Business Today

2018-08-30 247wallst
U.S. corporate profits boomed in the second quarter, boosted by large tax cuts and stronger economic growth than initially reported.
BF.B BF.A BFA AAPL

 
Brown-Forman Corp (BF.B) CEO Paul Varga on Q1 2019 Results - Earnings Call Transcript

2018-08-29 seekingalpha
Good morning. My name is Dorothy and I will be your conference operator today. At this time, I would like to welcome everyone to the Brown-Forman First Quarter Fiscal 2019 Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]. Thank you.
BF.B BF.A BFA

 
Jack Daniel’s maker suffering from trade war, with shares down 4.7 per cent this year

2018-08-29 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
BF.B BF.A BFA

 
Brown-Forman Corporation 2019 Q1 - Results - Earnings Call Slides

2018-08-29 seekingalpha
The following slide deck was published by Brown-Forman Corporation in conjunction with their 2019 Q1 earnings call.
BF.B BF.A BFA

 
Jack Daniel's maker Brown-Forman lowers profit forecast as tariffs bite

2018-08-29 reuters
(Reuters) - Brown-Forman Corp (BFb.N) (BFa.N) on Wednesday said tariffs would take a 6 cent bite out of its full-year profits and the Jack Daniel’s maker does not expect raising prices to immediately offset the dent.
BF.B BF.A BFA

6
Brown-Forman (BF.B) Tops Q1 Earnings & Sales, Trims View

2018-08-29 zacks
Brown-Forman Corporation (BF.B - Free Report) delivered first-quarter fiscal 2019 results, wherein both earnings and sales topped estimates. This marked the company’s fifth straight quarter of earnings and sales beat. Earnings per share of 41 cents increased 12% and surpassed the Zacks Consensus Estimate of 39 cents. Net sales improved about 6% year over year to $766 million and beat the Zacks Consensus Estimate of $756.
PRMW BF.B BF.A CCLAY BFA CCL CCLAF URBN SAM

 
Jack Daniel’s maker cuts profit forecast on trade war impact

2018-08-29 malaymail
BOSTON, Aug 29 — The trade war is having a tangible impact on the maker of Jack Daniel’s.
BF.B BF.A BFA

9
Brown-Forman Corporation (BF.B) Beats Q1 Earnings and Revenue Estimates

2018-08-29 zacks
Brown-Forman Corporation (BF.B - Free Report) came out with quarterly earnings of $0.41 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.37 per share a year ago. These figures are adjusted for non-recurring items.
BF.B EVLV BF.A BFA DY URBN

 
Brown-Forman posts higher profit in 1st quarter

2018-08-29 nzherald.co.nz
LOUISVILLE, Ky. (AP) — Brown-Forman Corp. on Wednesday reported fiscal first-quarter net income of $200 million.
BF.B BF.A BFA

 
Brown-Forman beats earnings and sales expectations, but cuts outlook citing competition and tariffs

2018-08-29 marketwatch
Brown-Forman Corp. BF.B, -0.59% reported Wednesday fiscal first-quarter earnings and sales that rose above expectations, but cut its full-year profit outlook citing "intense" competition and recently enacted retaliatory tariffs. The liquor seller's stock was still inactive in premarket trade. Net income for the quarter to July 31 increased to $200 million, or 41 cents a share, from $178 million, or 37 cents a share, in the same period a year ago.
BF.B BF.A BFA

 
Can Brown-Forman Corporation (BF.B) Keep the Earnings Surprise Streak Alive?

2018-08-27 zacks
If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Brown-Forman Corporation (BF.B - Free Report) . This company, which is in the Zacks Beverages - Alcohol industry, shows potential for another earnings beat.
BF.B BF.A BFA

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 115637209